natgillin/translations-raw huggingface dataset:
The vial should be held upright, shake gently and the aluminium cap and rubber stopper should be removed.
Vialo je treba držati pokonci, nežno pretresti in odstraniti aluminijasto zaporko in gumijasti zamašek.
The vial should be vented with a sterile syringe needle or a sterile non-siliconised mini-spike before withdrawing the dispersion.
Preden izvlečete disperzijo, zabodite v vialo sterilno injekcijsko iglo ali sterilno, nesilikonizirano mini-konico, da bo viala odzračena.
The vial should be well shaken until a slightly opaque white suspension is obtained.
Vialo je treba dobro pretresti, tako da nastane rahlo motna bela suspenzija.
The vial should never be opened and must be kept inside its tungsten shielding.
Viala se ne sme nikoli odpreti, ostati mora znotraj volframove zaščite.
The vial should then be shaken vigorously for one minute while keeping the filter and syringe attached.
Vialo nato močno stresajte eno minuto, pri čemer naj ostaneta filter in brizga pritrjena v njej.
The vial with NexoBrid powder must be shaken vigorously to fragment the NexoBrid powder cake.
Vialo s praškom NexoBrid morate močno stresati, da se pogača s praškom zdravila NexoBrid razdrobi.
The vial with powder is attached to the Raplixa spray device by inverting the device over the upright vial and pushing the vial into place.
Vialo s praškom je treba pritrditi na pripomoček RaplixaSpray tako, da se pripomoček obrne na glavo čez vialo, ki stoji navpik, in vstavi v vialo.
The vial, injection needle, filter needle and syringe are for single use only.
Viala, injekcijska igla, igla s filtrom in brizga so namenjene samo za enkratno uporabo.
The vials are closed with a halogenobutyl rubber stopper and sealed with an aluminium cap.
Viale so zaprte z zamaškom iz halogenbutilne gume in zavarjene z aluminijastim pokrovčkom.
The vials are for single use only.
Viale so namenjene samo za enkratno uporabo.
The vials are packed into a tungsten container for protective shielding.
Za zaščito so viale pakirane v volframovem vsebniku.
The vials should be opened under water or the content of the cup(s) should be poured into the water.
Viale je treba odpreti pod vodo ali vsebino meric(e) stresti v vodo.
The vials should not be frozen, heated or microwaved and should be protected from light.
Vial ni dovoljeno zamrzovati, segrevati in dajati v mikrovalovno pečico; zaščititi jih je treba pred svetlobo.
The vials should not be left outside the refrigerator longer than 24 hours prior to dilution for infusion.
Vial ni dovoljeno puščati zunaj hladilnika dlje kot 24 ur pred razredčitvijo za infundiranje.
THE VIALS SHOULD NOT BE SHAKEN
VIAL NE SMETE STRESATI
The vials should not be shaken.
Vial ni dovoljeno stresati.
The viral load was reduced to less than 50 copies/ml after 24 weeks in 90% (45 of 50) of patients.
Virusna obremenitev je bila po 24 tednih zmanjšana na manj kot 50kopij/ml pri 90 % (45 od 50) bolnikov.
The viral tropism cannot be safely predicted by treatment history and assessment of stored samples.
Tropizma virusa ni mogoče varno predvideti na podlagi anamneze o terapiji ali na podlagi ocene shranjenih vzorcev.
The virological responses of patients treated with Pegasys monotherapy and with Pegasys and ribavirin combination therapy in relation to genotype and pre-treatment viral load for HIV-HCV co- infected patients are summarised below in Table 20.
Virološki odzivi bolnikov, zdravljenih le z zdravilom Pegasys, in bolnikov, ki so se zdravili z zdravilom Pegasys v kombinaciji z ribavirinom, so v povezavi z genotipom in virusnim bremenom pred začetkom zdravljenja za bolnike, okužene s HCV in HIV, prikazani v preglednici 20.
The virus is found in body fluids such as in the vagina, blood, semen, or saliva (spit).
Virus se nahaja v telesnih tekočinah, npr. v nožnici, krvi, spermi ali slini (izpljunku).
The viruses have been selected because of their ‘low virulence’ (limited ability to cause the disease).
Virusi so bili izbrani zaradi njihove „nizke virulence“ (omejena zmožnost povzročiti bolezen).
The viruses in Versican Plus DHPPi are alive but they have been attenuated (weakened) so that they do not cause disease.
Virusi v cepivu Versican Plus DHPPi so živi, vendar so atenuirani (oslabljeni), tako da ne povzročajo bolezni.
The viruses included in the current formulation of Equilis Prequenza are grown in mammalian cells, unlike those in the initial formulation, which were grown in hens’ eggs.
Viruse, ki so vključeni v trenutno formulacijo cepiva Equilis Prequenza, gojijo v celicah sesalcev, virusi v prvotni formulaciji cepiva pa so bili gojeni v kokošjih jajcih.
The viruses included in the current formulation of Equilis Prequenza Te are grown in mammalian cells, unlike those in the initial formulation, which were grown in hens’ eggs.
Viruse, ki so vključeni v trenutno formulacijo cepiva Equilis Prequenza Te, gojijo v celicah sesalcev, virusi v prvotni formulaciji cepiva pa so bili gojeni v kokošjih jajcih.
The viruses used in Celvapan are grown in mammal cells (‘vero cells’), as opposed to hen’s eggs.
Virusi, uporabljeni pri cepivu Celvapan, so vzgojeni v celicah sesalcev (celicah vero) in ne v kokošjih jajcih.
The viruses used in Fluenz are grown in hens’ eggs.
Virusi, ki se uporabljajo v cepivu Fluenz, so vzrejeni v kokošjih jajcih.
The viruses used in Fluenz Tetra are grown in hens’ eggs.
Virusi, ki se uporabljajo v cepivu Fluenz Tetra, so vzgojeni v kokošjih jajcih.
The viruses used in Pandemic Influenza Vaccine H5N1 Baxter AG are grown in mammal cells (‘vero cells’), unlike those in some other flu vaccines, which are grown in hen’s eggs.
Viruse, ki so uporabljeni v zdravilu Pandemic Influenza Vaccine H5N1 Baxter AG, gojijo v celicah sesalcev („celicah Vero“), medtem ko viruse, uporabljene v nekaterih drugih cepivih proti gripi, gojijo v kokošjih jajcih.
The viruses used in Vepacel are grown in mammal cells (‘vero cells’), as opposed to hen’s eggs.
Virusi, uporabljeni pri cepivu Vepacel, so vzgojeni v celicah sesalcev (celicah vero) in ne v kokošjih jajcih.
The viruses used to obtain the surface antigen that are included in Optaflu are grown in mammalian cells, unlike those used for other flu vaccines, which are grown in hen’s eggs.
Viruse, ki se uporabijo za pridobitev površinskih antigenov, ki so nato vključeni v cepivo Optaflu, gojijo v celicah sesalcev, medtem ko viruse, uporabljene v drugih cepivih proti gripi, gojijo v kokošjih jajcih.
The vision of patients receiving Lucentis also remained better than the vision of those receiving sham injections in a study in which injections were given less frequently, with injections every month for the first three months and then every three months.
Tudi v študiji, v kateri so bolniki injekcije prejemali manj pogosto, in sicer prve tri mesece vsak mesec, nato pa vsake tri mesece, je vid pri bolnikih, ki so prejemali zdravilo Lucentis, ostal boljši od vida tistih, ki so prejemali navidezne injekcije.
The vitreous haze score gives an indication of inflammation with zero indicating no inflammation.
Stopnja motnosti steklovine odraža stopnjo vnetja, pri čemer stopnja nič pomeni stanje brez vnetja.
The VKA should be stopped.
Antagoniste vitamina K je treba ukiniti.
The volume (dose) of suspension should be administered orally within 30 minutes of mixing
Volumen (odmerek) suspenzije morate dati peroralno v 30 minutah po mešanju.
The volume (expressed in mL) of // Palivizumab // to be administered at one-monthly intervals = [patient weight in kg] multiplied by 0.15
Količina palivizumaba (izražena v ml), ki jo je potrebno injicirati v enomesečnih intervalih = [telesna masa bolnika v kg] pomnožena z 0,15.
The volume (in mL) required from the vial(s) should be calculated as follows: 0.3 x patient body weight (in kg).
Potrebno količino (v ml) iz vial(e) je treba izračunati takole: 0,3 x bolnikova telesna masa (v kg).
The volume administered per injection site in cattle should not exceed 7 ml.
Na eno mesto aplicirajte največ 7 ml.
The volume administered per injection site in dogs should not exceed 5 ml.
(Preberite povzetek glavnih značilnosti zdravila-SPC) Na eno mesto lahko aplicirate največ 5 ml zdravila.
The volume after mixing 1 vial of suspension (2.5 ml) with 1 vial of emulsion (2.5 ml) corresponds to
Količina, dobljena z mešanjem 1 viale suspenzije (2,5 ml) in 1 viale emulzije (2,5 ml), ustreza
The volume after mixing 1 vial of suspension (2.5 ml) with 1 vial of emulsion (2.5 ml) corresponds to 10 doses of vaccine (5 ml)
Količina, dobljena z mešanjem 1 viale suspenzije (2,5 ml) in 1 viale emulzije (2,5 ml), ustreza 10 odmerkom cepiva (5 ml).
The volume for injection is selected based on the patients' height and weight (Table 1).
Volumen za injiciranje se določi glede na bolnikovo višino in telesno maso (preglednica 1).
The volume for injection is selected based on the patients' height and weight.
Volumen za injiciranje se določi glede na bolnikovo višino in telesno maso.
The volume for injection is selected based on the patients' weight (Table 2).
Volumen za injiciranje se določi glede na telesno maso bolnika (preglednica 2).
The volume for injection is selected based on the patients' weight.
Volumen za injiciranje se določi glede na telesno maso bolnika.
The volume is 0.02-3 ml.
Volumen znaša 0,02–3 ml.
The volume is 0.02-5 ml.
Volumen znaša 0,02–5 ml.
The volume is 0.075 – 2 mL.
Prostornina znaša 0,075–2 ml.
The volume is 0.075 – 3.75 mL.
Prostornina znaša 0,075–3,75 ml.
The volume of concentrate (24 mg/ml docetaxel) corresponding to the required dose (mg) for the patient should be withdrawn (from the appropriate number of vials) using graduated syringes fitted with a needle.
Z graduiranimi injekcijskimi brizgami z iglo izvlecite količino koncentrata (24,4 mg/ml docetaksela), ki ustreza potrebnemu odmerku (mg) za bolnika (iz ustreznega števila vial).
The volume of diluted sodium pertechnetate (99mTc) solution for injection, added to the vial must be 1 ml.
Volumen razredčene raztopine natrijevega pertehnetata (99mTc) za injiciranje dodane v vialo mora biti 1 ml.
The volume of distribution (Vd) for AsIII is large (>400 L) indicating significant distribution into the tissues with negligible protein binding.
Volumen porazdelitve (Vd) za AsIII je velik (> 400 L), kar kaže na značilno porazdelitev v tkivu z zanemarljivo vezavo na beljakovine.
The volume of distribution (Vd) is 1.1 l x kg-1.
Volumen porazdelitve (Vd) je 1,1 l x kg-1.
The volume of distribution (Vss) was 4870 l (2640 l/m² for a patient with a median BSA of 1.84 m²) at steady state.
Volumen porazdelitve v stanju dinamičnega ravnovesja (Vss) je bil 4870 l (2640 l/m2 za bolnika z mediano telesno površino 1,84 m2).
The volume of distribution at steady state (Vss) was approximately 18-19 litres.
Volumen porazdelitve v stanju dinamičnega ravnovesja (Vss) je približno 18–19 litrov.
The volume of distribution at steady state adjusted for bioavailability is 0.57 l/kg in patients with Sickle Cell Syndrome (amounting to approximately 72 and 90 l in children and adults, respectively).
Volumen distiribucije pri vzpostavljenem ravnotežju zdravila, prilagojen biorazpoložljivosti, znaša pri bolnikih s srpasto celičnim sindromom 0,57 l/kg (to predstavlja približno 72 l pri otrocih in 90 l pri odraslih).
The volume of distribution at steady state is approximately 16.8 l, similar to extracellular fluid volume in man.
Porazdelitveni volumen zdravila v stanju dinamičnega ravnovesja je približno 16,8 l, kar je podobno volumnu zunajcelične tekočine pri človeku.
The volume of distribution at steady state was 8.64.1 l.
Porazdelitveni prostor v stanju ravnovesja je 8,6 ± 4,1 l.
The volume of distribution at steady-state (Vss) determined after intravenous administration was
Volumen distribucije v fazi stabilizacije koncentracije (V ), določen po intravenoznem vnosu je 11
The volume of distribution at steady-state (Vss) determined after intravenous administration was 13.2 L/kg.
Volumen distribucije v fazi stabilizacije koncentracije (VSS), določen po intravenoznem vnosu je 13,2 L/kg.
The volume of distribution at steady-state (Vss) was 9.3 l/kg and systemic clearance was 1.5 l/h/kg.
Volumen porazdelitve v dinamičnem ravnovesju (Vss) je bil 9,3 l/kg in sistemski očistek je bil 1,5 l/h/kg.
The volume of distribution at steady-state following intravenous administration is approximately 5.4 l.
Volumen porazdelitve v stanju dinamičnega ravnovesja po intravenskem dajanju je približno 5,41.
The volume of distribution corrected for weight ranged from 0.09 to 0.15 l/kg (mean ± S.D 0.12 ± 0.02 l/kg).
Telesni masi prilagojen volumen porazdelitve je bil v območju 0,09 do 0,15 l/kg (srednja vrednost  SD 0,12  0,02 l/kg).
The volume of distribution in blood is approximately 150ml/kg.
Volumen porazdelitve v krvi je približno 150 ml/kg.
The volume of distribution is 11 l after a single intravenous (IV) administration.
Volumen porazdelitve je 11 l po enkratnem intravenskem (i.v.) dajanju.
The volume of distribution is high (approximately 1000 litres), indicating extensive distribution.
Volumen porazdelitve je velik (približno 1000 litrov), kar kaže na obširno porazdelitev.
The volume of distribution of around 0.60 l/kg at steady state and clearance of around 101 ml/h/kg has been reported following a 10-minute infusion in dose range of 3-14 mg/m2.
Po 10-minutni infuziji odmerka 3-14 mg/m2 so v stanju dinamičnega ravnovesja zabeležili volumen porazdelitve približno 0,60 l/kg in očistek približno 101 ml/h/kg.
The volume of distribution of dabigatran of 60–70 L exceeded the volume of total body water indicating moderate tissue distribution of dabigatran.
Volumen porazdelitve dabigatrana, ki je 60 do 70 l, je bil večji od volumna skupne vode v telesu, kar kaže na zmerno porazdelitev dabigatrana v tkivih.
The volume of distribution of enoxaparin anti-Xa activity is about 5 litres and is close to the blood volume.
Volumen porazdelitve aktivnosti anti-Xa pri enoksaparinu znaša približno 5 l in je blizu volumnu krvi.
The volume of distribution of free aflibercept at steady-state is approximately 8 litres.
Volumen porazdelitve prostega aflibercepta v stanju dinamičnega ravnovesja je približno 8 litrov.
The volume of distribution of ONIVYDE 80 mg/m2 was 2.6 l/m2, which suggests that ONIVYDE is largely confined to vascular fluid.
Porazdelitveni volumen zdravila ONIVYDE 80 mg/m2 je bil 2,6 l/m2, kar kaže, da je zdravilo ONIVYDE večinoma omejeno na žilno tekočino.
The volume of distribution of rosiglitazone is approximately 14 l in healthy volunteers.
Volumen porazdelitve rosiglitazona je pri zdravih prostovoljcih približno 14 l.
The volume of distribution of thiotepa is large and it has been reported as ranging from 40.8 l/m2 to 75 l/m2, indicating distribution to total body water.
Volumen porazdelitve tiotepe je velik in se po poročanju giblje od 40,8 l/m2 do 75 l/m2, kar kaže na porazdelitev v vse tekočine v telesu.
The volume of distribution was 1050 L in healthy subjects given an intravenous dose of 2 mg.
Pri zdravih osebah, ki so dobile intravenski odmerek 2 mg, je bil volumen porazdelitve 1050 l.
The volume of distribution was estimated to be 193 l after intravenous administration of 5 mg oxybutynin hydrochloride.
Ocenjujejo, da je volumen porazdelitve po intravenski uporabi 5 mg oksibutininijevega klorida 193 l.
The volume of HUMENZA after mixing is at least 6 ml and allows the withdrawal of several doses (multidose vial).
Količina cepiva HUMENZA po mešanju je vsaj (6 ml) in zadošča za izvlek več odmerkov cepiva (večodmerna viala).
The volume of injected medicinal product and concentration dose range from 100 to 200 mg/mL did not affect the pharmacokinetics of a medicinal administration to healthy volunteers.
Injicirani volumen in koncentracija odmerka v območju od 100 do 200 mg/ml ne vplivata na farmakokinetiko dajanja zdravila zdravim prostovoljcem.
The volume of one vial ranges from 0.075 – 3.75 mL solution (corresponding to 3 – 150 GBq at activity reference time).
Prostornina ene viale je od 0,075 do 3,75 ml raztopine (kar ustreza od 3 do 150 GBq v referenčnem času aktivnosti).
The volume of one vial ranges from 1 to 3 mL solution (corresponding to 925 to 2,770 MBq at calibration time).
Ena viala vsebuje od 1 do 3 ml raztopine (kar ustreza od 925 do 2 770 MBq ob času kalibracije).
The volume of Prepandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) GlaxoSmithKline Biologicals 3.75 µg (5 ml) after mixing corresponds to 10 doses of vaccine.
Količina cepiva Prepandemično cepivo proti gripi (H5N1) (z delci virionov, inaktivirano, z adjuvansom) GlaxoSmithKline Biologicals 3,75 µg po mešanju (5 ml) ustreza 10 odmerkom cepiva.
The volume of reconstituted suspension corresponding to the calculated dose is extracted through the filter provided and further diluted with additional 50 ml sodium chloride 9 mg/ml (0.9 %) solution for injection according to the detailed instructions shown below.
Volumen rekonstituirane suspenzije, ki ustreza izračunanemu odmerku, se izvleče skozi priloženi filter in nato razredči z dodatnimi 50 ml raztopine natrijevega klorida 9 mg/ml (0,9 %) za injiciranje v skladu s podrobnimi navodili, ki so navedena spodaj.
The volume of reconstituted Xiapex to be administered into the plaque is 0.25 ml (for reconstitution instructions, see section 6.6, Table 13).
Volumen rekonstituiranega zdravila Xiapex, ki ga bomo dali v plak, je 0,25 ml (za navodila glede rekonstitucije glejte poglavje 6.6, preglednico 13).
The volume of sodium chloride 9 mg/mL (0.9%) solution for injection or 5% glucose injection should be adjusted so as not to exceed 5 mL/kg of patient weight at any given dose of Empliciti.
Volumen 0,9-% (9 mg/ml) raztopine natrijevega klorida za injiciranje ali 5-% raztopine glukoze za injiciranje morate prilagoditi tako, da pri katerem koli danem odmerku zdravila Empliciti ne presega 5 ml/kg telesne mase bolnika.
The volume of solvent required and the volume of reconstituted Xiapex to be administered into the Dupuytren’s cord differs depending on the type of joint being treated (for the reconstitution instructions, see section 6.6, Table 13).
Volumen potrebnega vehikla in volumen rekonstituiranega zdravila, ki ga bomo dali v Dupuytrenov vozlič, je odvisen od vrste sklepa, ki ga zdravimo (za navodila glede rekonstitucije glejte poglavje 6.6, preglednico 13).
The volume of stock solution is calculated using the volume of water that the pigs will drink during a 4-hour time period multiplied by the dosing pump rate (in decimal).
Količina osnovne raztopine se izračuna tako, da se količina vode, ki jo bodo prašiči popili v 4-urnem obdobju, pomnoži s hitrostjo črpalke za odmerjanje (v decimalkah).
The volume of suspension to be withdrawn for dose quantities is calculated as follows:
Volumen suspenzije, ki ga morate izvleči za določen odmerek, se izračuna na naslednji način:
The volume of the Adjupanrix vial after mixing is at least 5 ml.
Po mešanju je količina cepiva Adjupanrix v viali vsaj 5 ml.
The volume of the Arepanrix vial after mixing is at least 5 ml.
Po mešanju je količina cepiva Arepanrix v viali vsaj 5 ml.
The volume of the Pandemrix vial after mixing is at least 5 ml.
Po mešanju je količina cepiva Pandemrix v viali vsaj 5 ml.
The volume of the Prepandrix vial after mixing is at least 5 ml.
Po mešanju je količina cepiva Prepandrix v viali vsaj 5 ml.
The volume of the Prepandrix vial after mixing is at least 5 ml.
Po mešanju je količina cepiva Prepandrix v viali vsaj 5 ml..
The volume of the Pumarix vial after mixing is at least 5 ml.
Po mešanju je količina cepiva Pumarix v viali vsaj 5 ml.
The volume of the reconstituted suspension is 65 ml 1 ml contains 6 mg oseltamivir
Volumen rekonstituirane suspenzije je 65 ml 1 ml vsebuje 6 mg oseltamivirja
The volume of the reconstituted suspension is 75 ml 1 ml contains 12 mg oseltamivir
Volumen rekonstituirane suspenzije je 75 ml 1 ml vsebuje 12 mg oseltamivirja
The volume of unmedicated water in the stock suspension container has to be calculated taking as a basis the preset injection rate of the dosing pump and the volume of drinking water usually consumed by the animals in between 3 and 24 hours.
Volumen nemedicirane vode v tej posodi je treba izračunati tako, da vzamete za podlago prednastavljeno količino odmerne črpalke in volumen vode za pitje, ki jo živali običajno popijejo v 3 do 24 urah.
The volume or salt depletion should be corrected prior to the administration of Rasilamlo, or the treatment should start under close medical supervision.
Hipovolemijo ali pomanjkanje natrija je treba odpraviti pred dajanjem zdravila Rasilamlo ali pa je treba zdravljenje uvajati pod strogim zdravniškim nadzorom.
The volume per injection should not exceed 1 ml.
Količina na injekcijo ne sme preseči 1 ml.
The volume to be administered to a given patient should be calculated using the:
Volumen za uporabo pri določenem bolniku, se izračuna glede na:
The volume to be injected depends on the size of the tumour and the
Injicirana količina je odvisna od velikosti in števila tumorjev.
The volume to be injected should be calculated as follows:
Volumen raztopine za injiciranje je treba računati na sledeč način:
The VZV specific immune responses following Doses 1 and 2 were similar (see section 4.3).
Imunski odziv, specifičen za VZV, je bil podoben po 1. in 2. odmerku (glejte poglavje 4.3).
The VZV-specific immune responses to both vaccines at 4 weeks postvaccination were similar, whether administered concomitantly or nonconcomitantly.
Za VZV specifični imunski odziv na obe cepivi je bil 4 tedne po cepljenju podoben, ne glede na sočasno uporabo ali ne.
The VZV-specific immune responses to vaccine 6 weeks postvaccination was comparable in the booster dose and first dose group.
Za VZV specifični imunski odziv na cepivo je bil 6 tednov po cepljenju primerljiv v skupinah z obnovitvenim in s prvim odmerkom.
The warning in section 4.4 of the SmPC regarding bronchoconstriction is also be amended to clarify that that appropriate bronchodilator therapy and resuscitative measures are available for all patients prior to regadenoson administration (not just those with a history of bronchoconstrictive disease).
Opozorilo v poglavju 4.4 povzetka glavnih značilnosti zdravila glede bronhokonstrikcije je treba spremeniti s pojasnilom, da sta vsem bolnikom pred uporabo regadenozona (ne samo tistim, ki imajo v anamnezi bronhokonstriktorne bolezni) na voljo ustrezno zdravljenje z bronhodilatatorji in oživljanje.
The warning signs of a hypo may come on suddenly and can include: cold sweat; cool pale skin; headache; rapid heart beat; feeling sick; feeling very hungry; temporary changes in vision; drowsiness; unusual tiredness and weakness; nervousness or tremor; feeling anxious; feeling confused; difficulty in concentrating.
Opozorilni znaki hipe se lahko pojavijo nenadoma in lahko obsegajo: hladno znojenje, hladno in bledo kožo, glavobol, hitro bitje srca, obcutek slabosti, hudo lakoto, prehodne spremembe vida, zaspanost, nenavadno utrujenost in šibkost, živcnost ali tresenje, obcutek tesnobe, obcutek zmedenosti, težave s koncentracijo.
The warning signs of a hypo may come on suddenly and can include: cold sweat; cool pale skin; headache; rapid heart beat; feeling sick; feeling very hungry; temporary changes in vision; drowsiness; unusual tiredness and weakness; nervousness or tremor; feeling anxious; feeling confused; difficulty in concentrating.
Opozorilni znaki hipe se lahko pojavijo nenadoma in lahko obsegajo: hladno znojenje, hladno in bledo kožo, glavobol, hitro bitje srca, občutek slabosti, hudo lakoto, prehodne spremembe vida, zaspanost, nenavadno utrujenost in šibkost, živčnost ali tresenje, občutek tesnobe, občutek zmedenosti, težave s koncentracijo.
The water content of the breath sample will be kept mostly constant through Nafion water trap.
Stalno količino vode v vzorcu boste obdržali z vodno zaporo z nafionom.
The way Accofil is given, its dose and the duration of treatment depend on why it is being used, the patient’s body weight and the response to treatment.
Način dajanja zdravila Accofil, velikost odmerka in trajanje zdravljenja so odvisni od tega, zakaj se zdravilo uporablja, ter od telesne mase bolnika in njegovega odziva na zdravljenje.